Decoding Venoms. Advancing Medicine.

From Nature’s Deadliest Secrets to Humanity’s Next Medicines

  1. VenomSource precision molecules
  2. DecodeSequence genome, transcriptome & proteome
  3. ScreenHigh-throughput Electrophysiology
  4. AILearn function and selectivity
  5. EngineerDesign and engineer optimized proteins
  6. DrugAdvance therapeutic leads
The Venomics AI discovery pipeline progresses from venom through decoding, screening, AI analysis and synthesis to a drug candidate.
Backed by
Why Venomics AI

A discovery engine built on evolutionary intelligence.

20M+ unique bioactive peptides

Nature’s precision library

Millions of venom-derived peptides, evolved for potency and selectivity across biological targets.

100+ disease-relevant targets

Broad therapeutic reach

Searching nature’s molecular diversity across many disease-relevant targets

700M years of evolution

Evolution-optimised chemistry

Hundreds of millions of years of evolution. Built into every molecule.

भारत made in india

Built from India, for the world

Anchored in India’s extraordinary venom biodiversity and deep toxinology expertise.

The Precedent

This is not science fiction. Venom-derived drugs already exist.

Several important medicines were discovered from, or inspired by, venom.

FDA Approved 🐍

Captopril

Inspired by bradykinin-potentiating peptides in Brazilian pit viper (Bothrops jararaca) venom. The first ACE inhibitor to hit the market.

PEAK SALES: $1.6B / year
CLASS VALUE: $30B+

FDA Approved 1981

FDA Approved 🐚

Ziconotide (Prialt)

Derived from cone snail (Conus magus) toxin ω-conotoxin. A pioneering non-opioid analgesic for severe chronic pain.

POTENCY: 1,000× Morphine
TARGET MARKET: ~$70B (Pain)

FDA Approved 2004

FDA Approved 🦎

Exenatide (Byetta)

Based on exendin-4 from Gila monster (Heloderma suspectum) saliva. The foundational GLP-1 receptor agonist for type 2 diabetes.

PEAK SALES: $1.2B / year
CLASS VALUE: $20B+

FDA Approved 2005

Venomics AI is building a scalable discovery engine that transforms the intelligence encoded in venoms into new medicines.

Cone snail toxins pain therapeutics Gila monster saliva Exenatide / Byetta (diabetes) Brazilian pit viper Captopril (ACE inhibitor) Tarantula peptides chronic pain Sea anemone toxins autoimmune diseases Black mamba proteins analgesics Cone snail toxins pain therapeutics Gila monster saliva Exenatide / Byetta (diabetes) Brazilian pit viper Captopril (ACE inhibitor) Tarantula peptides chronic pain Sea anemone toxins autoimmune diseases Black mamba proteins analgesics
Healthcare Solutions

What Venomics AI is targeting

Six high-impact areas where venom biology offers transformative therapeutic and bio-agricultural potential.

Antimicrobial Resistance

The rapid emergence of antimicrobial resistance is outpacing the development of new antibiotics. Venom-derived peptides offer a promising source of novel antimicrobials capable of disrupting microbial membranes, enhancing host defence, and targeting pathogens through alternative mechanisms of action.

Venomics AI Focus

Discovering and engineering venom-derived antimicrobial molecules to combat drug-resistant pathogens and develop next-generation therapies for infectious diseases.

Diabetes & Weight Loss

Metabolic disorders represent one of the largest areas of unmet medical need and therapeutic opportunity. Venom-derived molecules have already demonstrated their potential in this field, notably through the development of GLP-1 receptor agonists, paving the way for new treatments targeting diabetes, obesity, and related metabolic diseases.

Venomics AI Focus

Discovering novel molecules that modulate appetite, glucose homeostasis, insulin secretion, energy balance, and metabolic signalling to develop targeted therapies for diabetes, obesity, and related metabolic disorders.

Senescence & Ageing Biology

Cellular senescence drives chronic inflammation, tissue dysfunction, fibrosis, and age-related diseases, while also influencing cancer progression. Venom-derived molecules offer promising opportunities to target senescence-associated pathways by modulating cellular signalling, stress responses, survival mechanisms, and immune interactions.

Venomics AI Focus

Discovering novel molecules to selectively identify, modulate, or eliminate pathological senescent cells, paving the way for therapies targeting ageing-associated diseases.

Ion Channels & Pain

Ion channels regulate pain signalling, neuronal activity, cardiac function, and cellular excitability. Animal venoms are exceptionally rich sources of potent and selective peptide modulators, offering promising opportunities for developing targeted therapeutics.

Venomics AI Focus

Targeting voltage-gated sodium, potassium, calcium, and other ion channels to develop novel therapeutics for pain, neurological disorders, and related conditions.

Cancer

Cancer cells exhibit altered signalling, metabolism, membrane composition, and immune regulation, creating vulnerabilities that can be therapeutically targeted. Venom-derived molecules offer promising opportunities to exploit these vulnerabilities by interacting with specific receptors, ion channels, cellular membranes, and cancer-associated signalling pathways.

Venomics AI Focus

Developing venom-inspired molecules for tumour targeting, cytotoxicity, imaging, and precision oncology.

Bioinsecticides

Conventional chemical pesticides are increasingly compromised by pest resistance and their adverse environmental impacts. Animal venoms offer a promising alternative, having evolved potent toxins that selectively target insect ion channels and neuroreceptors to rapidly immobilise prey or deter predators.

Venomics AI Focus

Transforming venom toxins into selective, biodegradable, environmentally friendly bioinsecticides for sustainable crop and vector protection.

The Founders

Meet the minds behind the mission

A multidisciplinary team spanning toxinology, computational biology, and machine learning.

Co-founder and Director
Prof. Kartik Sunagar
Prof. Kartik Sunagar
Co-founder, Director
Professor, Centre for Ecological Sciences, Indian Institute of Science, Bengaluru

An evolutionary biologist at the Indian Institute of Science, Bengaluru, Prof. Sunagar has built one of India’s leading venom research programs. His work spans venom evolution, snakebite therapeutics, antibody discovery, small-molecule inhibitors, and the translational use of venom biology for medicine.

101Publications
6,561Citations
40h-index
72i10-index
36Journals
Co-founder and CTO
Dr. Vinay Prabhu
Dr. Vinay Prabhu
Co-founder, CTO
PhD, Electrical & Computer Engineering Carnegie Mellon University MSEE · IIT Madras

Dr. Prabhu brings deep expertise in machine learning, large-scale AI systems, and computational biology. At Venomics AI, he leads the development of AI platforms that convert venom datasets into therapeutic insights and drug discovery programs.

42Publications
5,571Citations
13h-index
19i10-index
XJournals
Our Team
Scientific Foundation

Built on peer-reviewed science

Our platform builds on years of peer-reviewed research in venom biology, toxin pharmacology, and snakebite therapeutics.

Publications Archive
Field Notes

Dispatches from the Venom Detective

Stories from Prof. Kartik Sunagar on venom biology, snakebite, evolution, and the adventures that connect them.

All Field Notes
Updates

Latest Developments

Key milestones, funding announcements, and press features from the Venomics AI team.

A luminous peptide structure flowing into an accelerated-computing network, representing Venomics AI joining NVIDIA Inception
Award Latest · August 20, 2026

Venomics AI Joins NVIDIA Inception

Venomics AI has been accepted into NVIDIA Inception, a program supporting startups advancing technology through AI and accelerated computing.

Accelerating our work at the intersection of venom biology and AI.

Award Announcement
Venomics AI featured among the 2026 Indo-Boston Biotech Bridge Award Top 5
Award July, 2026

Top 5 Indo-Boston Biotech Bridge Award Finalist

Venomics AI has been selected among the Top 5 companies for the 2026 Indo-Boston Biotech Bridge Award.

Recognized by Nucleate India and ABLE, powered by LabCentral.

Award Announcement
A venom sample, molecular model and illuminated screening platform representing Venomics AI's funding milestone
Funding April, 2026

$3M Funding Raised

Venomics AI raised ~$3M in pre-seed funding to establish its integrated venom-to-therapeutics discovery platform.

Capital to build the discovery platform.

Funding Announcement
An illuminated peptide structure and AI network above a laboratory screening plate representing the Anthropic AI for Science Grant
Grant August, 2026

Anthropic AI for Science Grant

Kartik Sunagar’s Evolutionary Venomics Lab at IISc has been awarded Anthropic AI for Science Grant to use Claude to annotate venom data and find shared targets for next-generation antivenoms.

Addressing a nationwide problem that kills an estimated 58,000 people a year.

Grant Announcement
All Updates
Get In Touch

Let's build the future of medicine together

Whether you're an investor, scientist, or patient advocate, we want to hear from you.

Direct contact info [at] venomics.ai

Partnerships, licensing, investor conversations, media, and scientific collaborations.

Location

No 33, 4th Floor, 1st Main, Ganganagar Gramatana, HMT, R T Nagar, Bengaluru 560032, Karnataka, India

Company Incorporation Number (CIN): U72100KA2026PTC220933

Grievance Officer: Purba Sarkar (grievance@venomics.ai)

Send us a message